Analyst Reco. Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
7.75 ^USD	+1.31%		+8.54%	+14.81%

03-18	Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	MT
03-18	Fulcrum Therapeutics, Inc. Announces Executive Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating	02-28	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating	01-25	MT
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5	23-08-23	MT
Stifel Upgrades Fulcrum Therapeutics to Buy From Hold, Raises Price Target to $11 From $4	23-08-22	MT
Oppenheimer Adjusts Fulcrum Therapeutics Price Target to $16 From $20, Maintains Outperform Rating	23-05-16	MT
HC Wainwright Adjusts Price Target on Fulcrum Therapeutics to $5 From $6, Maintains Neutral Rating	23-05-16	MT
Stifel Lowers Fulcrum Therapeutics' Price Target to $4 From $6, Hold Rating Kept	23-05-15	MT
Goldman Sachs Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $3 From $9	23-05-04	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $9 From $17, Maintains Buy Rating	23-03-13	MT
Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts Price Target to $6 From $35	23-03-10	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $7 From $8, Maintains Equalweight Rating	23-03-10	MT
Credit Suisse Downgrades Fulcrum Therapeutics to Neutral From Outperform, Adjusts Price Target to $8 From $11	23-03-10	MT
HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-10	MT
Morgan Stanley Downgrades Fulcrum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $8 From $27	23-02-28	MT
Oppenheimer Adjusts Fulcrum Therapeutics' Price Target to $20 From $26, Maintains Outperform Rating	23-02-27	MT
Credit Suisse Lowers Fulcrum Therapeutics' PT to $11 From $19, Says FTX-6058 Clinical Hold Introduces Near-Term Uncertainty; Keeps Outperform Rating	23-02-27	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $27 From $26, Maintains Overweight Rating	23-01-24	MT
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $21 From $18, Maintains Overweight Rating	23-01-23	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $17 From $11, Maintains Buy Rating	23-01-19	MT
Goldman Sachs Starts Fulcrum Therapeutics at Buy With $11	22-11-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Analyst Reco.

Filters